Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia

Postgraduate Medical Journal

Volumn 72, Issue 854, 1996, Pages 739-743

  Betteridge, D John ^a   O'Bryan Tear, C Gillies ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b Sanofi Winthrop Limited   (United Kingdom)

Author keywords

Bezafibrate; Ciprofibrate; Hyperlipidaemia type II; Hypolipidaemic agents

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALOPECIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 0030466926     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.72.854.739     Document Type: Article

References (28)

1. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981; 283: 179-86.
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-8.
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality, implications from a cohort of 361,662 men. Lancet 1986; 933-6.
4. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363-6.
5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
7. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary anery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-7.
8. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study - implications for treatment. Circulation 1992; 85: 37-45.
9. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia: a double blind trial. Atherosclerosis 1982; 44: 211-21.
10. Brown DF, Beyler A, Daudiss K. Effective therapy in type II hyperlipidaemia with a new long acting drug, Ciprofibrate. Am J Cardiol 1979; 43: 409.
11. Davignon J, Gascon B, Brossard D, Quidoz S, Leboeuf N, Lelorier J. The use of Ciprofibrate in the treatment of familial hyperlipidaemias. In: Noseda G, ed, Lipoproteins and coronary atherosclerosis. Amsterdam: Elsevier, 1982; pp 213-21.
12. Michel G, Brouckaert A. An epidemiological study of hypercholesterolaemia in Luxembourg. Bull Soc Sci Med Grand-Duche Luxemb 1990; 127: 35-9.
13. Cattin L, Da Col PG, Feruglio FS, et al. Efficacy of Ciprofibrate in primary type II and IV hyperlipidaemia: the Italian multicentre study. Clin Ther 1990; 12: 482-8.
14. De Gennes JL, Truffert J, Dairou F. Evaluation of the serum lipid lowering effect and tolerance of Ciprofibrate. Sem Hop Paris 1985; 61: 2807-12.
15. Schifferdecker E, Rosak C, Schößling K. Langzeithandlung mit dem lipidsenker Ciprofibrat. [Long-term treatment by the lipid-Iowering agent Ciprofibrate.] Inn Med 1984; 11: 107-12.
16. Turpin G. Étude extensive d'un hypolipidémiant le bezafibrate en médecine générale. [Extensive study on bezafibrate as lipid-lowering agent in general medicine.] Gas Med 1986; 93: 57-63.
17. Rouffy J, Goy-Loeper J, Chanus B, Bakir R, Djain F. Étude comparative de l'action hypolipidémiante du bezafibrate et du fénofibrate chex vingt patients présentant une hyperlipoprotéinémie de type II avec hypo-HDL-émie. [Comparative study of reduction in serum lipids obtained with bezafibrate and fenofibrate in twenty patients with type II hyperlipoproteinemia and low serum HDL.] Sem Hop Paris 1985; 61: 2115-20.
18. Mordasini GF, Riesen W, Oster P, Riva G, Verhalten de high density-Lipoproteine (HDL) unter medikamentoser lipidsenkender Behandlung. [Behaviour of high-density lipoproteins in drug lipid-lowering treatment.] Schweiz Med Wochenschr 1982; 112: 95-7.
19. Martini S, Valerio G, Fellin R, Baggio G, Gasparptto A. Bezafibrate and clofibrate: effects on plasma lipids, lipoproteins and apoproteins compared in familial hypocholesteraemia. Curr Ther Res 1982; 31: 354-61.
20. The Expert Panel. Report of the national Cholesterol Education Programme Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-45.
21. European Atherosclerosis Society Study Group. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9: 571-600.
22. Warnick GR, Benderson J, Albers JJ, et al. Dextran sulphate-magnesium precipitation procedure for quantification of high density lipoprotein cholesterol. Clin Chem 1982; 28: 1379-88.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499.
24. Arntz HR, Blankart-von-Roll R, Holler HD, et al. Behandlung der Hypercholesterinaimie. Multizentrische Vergleichsstudie zwischen bezafibrat un bezafibrat retard. [Treatment of hypercholesteremia. Multicentre comparison between bezafibrate and bezafibrate retard.] Munch Med Wochenschr 1985; 127/9: 206-9.
25. Farnier M, Troung-Tan N, Regy C. Comparative multicentre trial of the efficacy and tolerability of ciprofibrate and simvastatin in the treatment of mixed type lib hyperlipoproteinaemias. J Drug Dev 1992; 5: 13-21.
26. Bruckert E, Gheron G, Dairou F, Comparisons of the efficacy and tolerance of ciprofibrate and gemfibrozil in the treatment of type Ha and lib hyperlipidaemias. Synthèse Méd 1994; 429: 14-16.
27. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronised fenofibrate and simvastatin in patients with primary type Ha or lib hyperlipidaemia. Arch Intern Med 1994; 154: 441-9.
28. Weisweiler P. Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acetyltransferase activity in familial hypercholesterolaemia. Eur J Clin Pharmacol 1988; 35: 579-83.